← SynDRA
ATOVAQUONE
SynDRA canonical compound SYN0007078 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Mechanism of action | mitochondrial electron transport inhibitor |
| Indication | pneumonia |
| Disease area | infectious disease |
All known targets
- ABCG2
- DHODH
- Dhodh
- MT-CYB
- Malaria DHOdehase
- dhod
Mechanisms of action (all sources)
- mitochondrial electron transport inhibitor
- Inhibitor
- MT-CYB INHIBITOR
Drug classes
- Antimalarial
- Antiprotozoal
- Anti-Infective Agents
- Antimalarials
- Antiparasitic Agents
- Antiprotozoal Agents
- Enzyme Inhibitors
ATC classes
- P01A · AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
- ANTIMALARIALS
Cross-references
Synonyms
- 566C80
- mepron
- Atovacuona
- 566C
- NSC-759582
- Atovaquone component of malarone
- Atovaquone component of malarone pediatric
- Mepron
- Wellvone
- Acuvel
- Atavaquone
- Pron
- Atovaquone GlaxoSmithKline brand
- Glaxo Wellcome brand of atovaquone
- GlaxoSmithKline brand of atovaquone
- Malarone Pediatric
- BW 566C
- BW 566C80
- Hydroxynaphthoquinone 566C80
- Atovaquone & Interleukin 12
- BW 556C-80
- BW 566C-80
- BW-A 566C
- DRG-0084
- Hydroxynaphthoquinone, 566C80
- Mepron (TN)
- Mepron (antipneumocystic)
- ATO & IL-12
- Atovaquone (USP/INN)
- Atovaquone [USAN:BAN:INN]
- CRL-8131 & Atovaquone
- 2-(4-(4'-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
- 2-(4-(4-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
- 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
- 2-(trans-4-(p-Chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone
- 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
- 2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxynaphthalene-1,4-dione
- 2-[trans-4-(p-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
Reported adverse events
- Insomnia
- Nausea
- Vomiting
- Stevens-Johnson syndrome
- Headache
- Hepatotoxicity
- Cough
- Erythema
- Erythema multiforme
- Hepatitis
- Hypersensitivity
- Pancreatitis
Look up ATOVAQUONE in the interactive SynDRA portal →